CClinicalTrials.gg
RecruitingNCT07741968Updated Aug 10, 2026

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

An interventional study of Best Practice and Interview in Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage III Breast Cancer AJCC v8, sponsored by City of Hope Medical Center. Recruiting at 11 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This clinical trial studies whether an intervention supported by technology (blended e-health intervention) works to improve fear of progression (FOP) in women with gynecologic or breast cancer. FOP is the fear patients experience from the possibility that their cancer could grow, spread, or get worse. Managing FOP is a leading unmet concern of cancer patients. High levels of FOP are associated with distress, depression, and increased health care costs, despite this, access to resources to address FOP remain limited. The blended e-health intervention in this trial offers remote group sessions along with online sessions to help patients access the information. Session content incorporates values-based goal setting and skills practices to manage unhelpful beliefs about worry and promote helpful coping behaviors. The sessions may help patients recognize unhelpful thoughts and behaviors which reinforce worry. A blended e-health intervention may be an effective way to improve FOP in women with gynecologic or breast cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the feasibility and acceptability of a blended e-health intervention to manage FOP in patients with stage III or IV gynecologic (GYN) or breast cancer.

SECONDARY (EXPLORATORY) OBJECTIVE:

I. To determine the effects of the intervention on reducing fear of cancer progression (FOP) (primary outcome) and improving secondary outcomes of distress, anxiety, metacognitions, and mindfulness.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients participate in the Mindful Living Program over 6 weeks consisting of group sessions over 60 minutes each during weeks 1, 3, and 6 and online sessions during weeks 2, 4, and 5. Patients also practice skills related to attention training, detached mindfulness, worry postponement, guided imagery, and other mindfulness practices 10-12 minutes daily for 6 days a week. Additionally, patients receive a check-in call over 15-20 minutes at week 3-4 and access to videos as well as a website containing a journal, community forum, and resource library on study.

ARM II: Patients participate in the Navigating Cancer Program over 6 weeks consisting of group sessions over 60 minutes each during weeks 1, 3, and 6 and online sessions during weeks 2, 4, and 5. Patients also receive a check-in call over 15-20 minutes at week 3-4.

After completion of study intervention, patients are followed up at week 12.

02

Conditions studied

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Breast Carcinoma
  • Breast Mixed Epithelial/Mesenchymal Metaplastic Carcinoma
  • Endometrial Carcinoma
  • Malignant Female Reproductive System Neoplasm
  • Ovarian Carcinoma
  • Ovarian Carcinosarcoma
  • Stage III Cervical Cancer AJCC v8
  • Stage III Vaginal Cancer AJCC v8
  • Stage III Vulvar Cancer AJCC v8
  • Stage IV Cervical Cancer AJCC v8
  • Stage IV Vaginal Cancer AJCC v8
  • Stage IV Vulvar Cancer AJCC v8
  • Triple-Negative Breast Carcinoma
  • Uterine Corpus Carcinosarcoma
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women with stage III or IV GYN (ovarian, endometrial, cervical, vulvar/vaginal) or breast cancer who are at least 2 months from initial diagnosis OR Women with stage I or II endometrial, ovarian, or breast cancer with carcinosarcoma histology OR Women with stage I or II triple negative breast cancer
  • Score ≥ 34 on the Fear of Progression Short-Form, indicating dysfunctional levels
  • Age 18 or older; able to read and understand English
  • Patients can be on active treatment or surveillance. They can be no evidence of disease (NED), recurrent or with progressive disease

Exclusion criteria

Exclusion Criteria:

  • Enrolled in hospice
  • Ongoing uncontrolled active psychiatric condition that, in the opinion of the investigator, would interfere in the conduct of the study (e.g., mood disorders, psychosis disorders, or substance use), Major depression as assessed by Patient Health Questionnaire-9 (PHQ-9)
  • Non-English speaking
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
  • Current participation in a mind-body or mindfulness education program within the past six weeks
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Arm I (Mindful Living Program)

    Patients participate in the Mindful Living Program over 6 weeks consisting of group sessions over 60 minutes each during weeks 1, 3, and 6 and online sessions during weeks 2, 4, and 5. Patients also practice skills related to attention training, detached mindfulness, worry postponement, guided imagery, and other mindfulness practices 10-12 minutes daily for 6 days a week. Additionally, patients receive a check-in call over 15-20 minutes at week 3-4 and access to videos as well as a website containing a journal, community forum, and resource library on study.

    Other: Interview · Other: Supportive Care · Other: Survey Administration · Behavioral: Telephone-Based Intervention

  • Active comparator
    Arm II (Navigating Cancer Program)

    Patients participate in the Navigating Cancer Program over 6 weeks consisting of group sessions over 60 minutes each during weeks 1, 3, and 6 and online sessions during weeks 2, 4, and 5. Patients also receive a check-in call over 15-20 minutes at week 3-4.

    Other: Best Practice · Other: Interview · Other: Survey Administration · Behavioral: Telephone-Based Intervention

Interventions

  • OtherBest Practice

    Participate in Navigating Cancer Program

    Also known as: standard of care, standard therapy

  • OtherInterview

    Ancillary studies

  • OtherSupportive Care

    Participate in Mindful Living Program

    Also known as: Supportive Therapy, Symptom Management, Therapy, Supportive

  • OtherSupportive Care

    Complete skills practice

    Also known as: Supportive Therapy, Symptom Management, Therapy, Supportive

  • OtherSupportive Care

    Receive access to videos and website

    Also known as: Supportive Therapy, Symptom Management, Therapy, Supportive

  • OtherSurvey Administration

    Ancillary studies

  • BehavioralTelephone-Based Intervention

    Receive check-in call

05

What researchers measure

Primary outcomes

  1. Recruitment rate (Feasibility of enrollment)

    Recruitment rate will be sufficient if at least 45% of invited patients complete the screening questionnaire and are enrolled. Descriptive statistics will be used to analyze feasibility measures.

    Time frame: Up to 18 months

  2. Attrition rate (Intervention feasibility)

    Attrition will be acceptable if the percentage of enrolled subjects who drop out does not exceed 30% by week 6. Descriptive statistics will be used to analyze feasibility measures.

    Time frame: Up to 6 weeks

  3. Percentage of Attendance/Sessions Completed

    Percentage of Attendance: Defined as the proportion of enrolled participants who attend the intervention sessions according to the study protocol. Feasibility will be evaluated based on participant attendance and will be considered successful if predefined feasibility criteria are met. Sessions Completed: Defined as the average number of intervention sessions completed by participants during the study period. This measure will be used to assess participant engagement with the intervention. Feasibility will be considered successful if predefined feasibility criteria are met.

    Time frame: Up to 6 weeks

  4. System Usability Scale survey (Acceptability)

    The System Usability Scale is a validated measure of system usability with scores ranging from 0 to 100, where higher scores indicate greater perceived usability. The mean score will be calculated among participants who complete the assessment. Acceptability and usability will be considered successful if the mean score meets predefined study criteria.

    Time frame: At week 6 (T2)

  5. Engagement measures

    Number of Log-ins: Defined as the average number of times participants log in to the study website during the study period. Page Views: Defined as the average number of website pages viewed by participants during the study period. Total Time on Site: Defined as the average total time participants spend on the study website during the study period. Skills Video Access: Defined as the average number of times participants access skills practice videos during the study period. Time Spent Viewing Skills Videos: Defined as the average total time participants spend viewing skills practice videos during the study period. Most Frequently Visited Content: Defined as the website content or pages accessed most frequently by participants during the study period, measured by access frequency.

    Time frame: Up to 6 weeks

  6. Themes From Open-Ended System Usability Scale Responses and Open-Ended Exit Interview Questions

    Defined as themes identified from participants' responses to open-ended System Usability Scale questions. Qualitative data will be analyzed using conventional content analysis to identify common perceptions, experiences, and suggestions regarding website usability. Defined as themes identified from participants' responses to open-ended exit interview questions. Qualitative data will be analyzed using conventional content analysis to identify participants' experiences, perceived benefits, barriers to engagement, and recommendations for improvement.

    Time frame: Up to 14 months

  7. Change in fear of progression

    Measured using the Fear of Progression Questionnaire. Total scores range from 12 to 60, with higher scores indicating greater fear of cancer progression. Change from baseline will be assessed.

    Time frame: At baseline (T1), 6 weeks (T2), and 12 weeks (T3)

Secondary outcomes

  1. Change in cancer-specific distress

    Measured using a cancer-specific distress instrument. Total scores range from 0 to 88, with higher scores indicating greater cancer-related distress. Change from baseline will be assessed.

    Time frame: At baseline (T1), 6 weeks (T2) and 12 weeks (T3).

  2. Change in Anxiety (PROMIS Anxiety 8a):

    Measured using the PROMIS Anxiety 8a scale. Scores range from 37.1 to 83.1, with higher scores indicating greater anxiety. Change from baseline will be assessed.

    Time frame: At Baseline (T1), 6 weeks (T2) and 12 weeks (T3).

  3. Change in metacognitions

    Measured using the Metacognitions Questionnaire. Subscale scores range from 6 to 24, with higher scores indicating more dysfunctional beliefs about worry and metacognitive processes. Change from baseline will be assessed

    Time frame: At Baseline (T1), 6 weeks (T2) and 12 weeks (T3).

  4. Change in mindfulness

    Measured using the Five Facet Mindfulness Questionnaire (FFMQ). Total scores range from 12 to 60, with higher scores indicating greater engagement with mindfulness skills and mindful awareness. Change from baseline will be assessed.

    Time frame: At Baseline T1, 6 weeks (T2) and 12 weeks (T3)

06

Study locations

11 of 11 sites recruiting
  • City of Hope at Arcadia
    Arcadia, California 91007, United States
    Recruiting
  • City of Hope Medical Center
    Duarte, California 91010, United States
    • Anne Reb · Contact · areb@coh.org · 626-218-4673
    • Anne Reb · Principal investigator
    Recruiting
  • City of Hope at Seacliff
    Huntington Beach, California 92648, United States
    Recruiting
  • City of Hope at Irvine Lennar
    Irvine, California 92618, United States
    • Anne Reb · Contact · areb@coh.org · 626-218-4673
    • Anne Reb · Principal investigator
    Recruiting
  • City of Hope Antelope Valley
    Lancaster, California 93534, United States
    Recruiting
  • City of Hope at Long Beach Elm
    Long Beach, California 90813, United States
    Recruiting
  • City of Hope at Santa Clarita
    Santa Clarita, California 91355, United States
    Recruiting
  • City of Hope at Simi Valley
    Simi Valley, California 93065, United States
    Recruiting
  • City of Hope at South Pasadena
    South Pasadena, California 91030, United States
    Recruiting
  • City of Hope at Upland
    Upland, California 91786, United States
    Recruiting
  • City of Hope at West Covina
    West Covina, California 91790, United States
    Recruiting
07

Registry details

Key details

Study ID
NCT07741968
Lead sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Feb 22, 2027 (estimated)
Primary completion
Jan 16, 2028 (estimated)
Completion
Jan 16, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Anne Reb
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion